Patents Assigned to Forty Seven, Inc.
-
Patent number: 11891450Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.Type: GrantFiled: February 11, 2019Date of Patent: February 6, 2024Assignee: Forty Seven, Inc.Inventors: Mark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer
-
Patent number: 11802153Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.Type: GrantFiled: October 18, 2018Date of Patent: October 31, 2023Assignee: Forty Seven, Inc.Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
-
Patent number: 11795223Abstract: Methods, kits, and compositions are provided herein that can be used to treat hematopoietic disorders using an anti-CD47 agent such as an antibody and a hypomethylating agent, such as azacitidine.Type: GrantFiled: October 16, 2020Date of Patent: October 24, 2023Assignee: Forty Seven, Inc.Inventors: Yinuo Cao, Mark Ping Chao, Ravindra Majeti, Roy Louis Maute, Chris Hidemi Mizufune Takimoto, Kelly Tran
-
Patent number: 11753480Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.Type: GrantFiled: February 22, 2021Date of Patent: September 12, 2023Assignee: Forty Seven, Inc.Inventors: Jie Liu, Jens-Peter Volkmer
-
Patent number: 11643461Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.Type: GrantFiled: November 20, 2020Date of Patent: May 9, 2023Assignee: Forty Seven, Inc.Inventors: Marie Châlons-Cottavoz, Mehdi Lahmar, Klaus Schwamborn, Nicola Beltraminelli, Stéphanie Fallot, Pierre Garrone
-
Patent number: 11208482Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.Type: GrantFiled: November 25, 2019Date of Patent: December 28, 2021Assignee: FORTY SEVEN, INC.Inventors: Jie Liu, Kavitha Sompalli
-
Patent number: 11141480Abstract: Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.Type: GrantFiled: June 21, 2018Date of Patent: October 12, 2021Assignees: The Board of Trustees of the Leland Stanford Junior University, Forty Seven, Inc.Inventors: Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman
-
Patent number: 11041022Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.Type: GrantFiled: December 29, 2020Date of Patent: June 22, 2021Assignee: FORTY SEVEN, INC.Inventors: Jie Liu, Kavitha Sompalli
-
Patent number: 10961318Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.Type: GrantFiled: July 25, 2018Date of Patent: March 30, 2021Assignee: Forty Seven, Inc.Inventors: Jie Liu, Jens-Peter Volkmer
-
Patent number: 10927173Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.Type: GrantFiled: January 11, 2017Date of Patent: February 23, 2021Assignee: Forty Seven, Inc.Inventors: Marie Chalons-Cottavoz, Mehdi Lahmar, Klaus Schwamborn, Nicola Beltraminelli, Stephanie Fallot, Pierre Garrone
-
Publication number: 20200165337Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.Type: ApplicationFiled: November 25, 2019Publication date: May 28, 2020Applicant: Forty Seven, Inc.Inventors: Jie Liu, Kavitha Sompalli
-
Patent number: 10611842Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.Type: GrantFiled: July 26, 2017Date of Patent: April 7, 2020Assignees: The Board of Trustees of the Leland Stanford Junior University, FORTY SEVEN, INC.Inventors: Jie Liu, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman
-
Publication number: 20190023784Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.Type: ApplicationFiled: January 11, 2017Publication date: January 24, 2019Applicant: Forty Seven, Inc.Inventors: Marie Chalons-Cottavoz, Mehdi Lahmar, Klaus Schwamborn, Nicola Beltraminelli, Stephanie Fallot, Pierre Garrone